Salicylic Augmentation in Depression
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Depression
- Depressive Disorder
- Major Depressive Disorder
- Treatment Resistant Depression
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomized control trial with about half of all participants receiving placebo.Masking: Double (Participant, Investigator)Masking Description: Study team will be blinded to participant condition. Pharmacy will be responsible for providing study drug versus identical placebo to participants.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
This study is a randomized, double-blind, placebo-control trial. The primary aims of this study are: Aim 1: To evaluate the clinical effect of aspirin augmentation on depression. Aim 2: To assess the inflammatory profile of the blood of the aspirin augmentation responders compared with the non-respo...
This study is a randomized, double-blind, placebo-control trial. The primary aims of this study are: Aim 1: To evaluate the clinical effect of aspirin augmentation on depression. Aim 2: To assess the inflammatory profile of the blood of the aspirin augmentation responders compared with the non-responders. Aim 3: To evaluate whether immune gene expression patterns are associated with antidepressant response to aspirin. Aim 4: To collect samples for later, more detailed immunologic characterization.
Tracking Information
- NCT #
- NCT03152409
- Collaborators
- Columbia University
- Investigators
- Principal Investigator: Jessica Harder, MD Brigham and Women's Hospital
Get Well Soon